Cargando…
Silibinin: an old drug for hematological disorders
INTRODUCTION: Silibinin (silybin), a non-toxic natural polyphenolic flavonoid, is the principal and the most biologically active component of silymarin. It is efficient in the treatment of acute and chronic liver disorders caused by toxins, drug, alcohol, hepatitis, and gall bladder disorders. Furth...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687691/ https://www.ncbi.nlm.nih.gov/pubmed/29179521 http://dx.doi.org/10.18632/oncotarget.19153 |
_version_ | 1783279010526003200 |
---|---|
author | Zou, Hai Zhu, Xing-Xing Zhang, Guo-Bing Ma, Yuan Wu, Yi Huang, Dong-Sheng |
author_facet | Zou, Hai Zhu, Xing-Xing Zhang, Guo-Bing Ma, Yuan Wu, Yi Huang, Dong-Sheng |
author_sort | Zou, Hai |
collection | PubMed |
description | INTRODUCTION: Silibinin (silybin), a non-toxic natural polyphenolic flavonoid, is the principal and the most biologically active component of silymarin. It is efficient in the treatment of acute and chronic liver disorders caused by toxins, drug, alcohol, hepatitis, and gall bladder disorders. Further, in our previous studies, we explored the anti-cancer efficacy in common cancers, such as lung, prostatic, colon, breast, bladder, as well as, hepatocellular carcinoma. Interestingly, silibinin is still not solely limited to the treatment of these diseases. Recent research endeavors suggest that silibinin may function diversely and serve as a novel therapy for hematological disorders. AREAS COVERED: It discovered several interesting viewpoints in the widely studied mechanisms of silibinin in the hematological disorders. EXPERT COMMENTARY: In this report, we review the up-to-date findings of more potency roles of silibinin in β-thalassemia (β-TM), acute myeloid leukemia (AML), anaplastic large cell lymphoma (ALCL) and multiple myelomas (MM) therapy and attempt to clarify the mechanisms underlying its effects. There are two viewpoints: First, The functional mechanisms of silibinin in AML cells via regulating cell differentiation to exert anti-cancer effect; Second, combination treatment strategy may be a good choice. |
format | Online Article Text |
id | pubmed-5687691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56876912017-11-20 Silibinin: an old drug for hematological disorders Zou, Hai Zhu, Xing-Xing Zhang, Guo-Bing Ma, Yuan Wu, Yi Huang, Dong-Sheng Oncotarget Review INTRODUCTION: Silibinin (silybin), a non-toxic natural polyphenolic flavonoid, is the principal and the most biologically active component of silymarin. It is efficient in the treatment of acute and chronic liver disorders caused by toxins, drug, alcohol, hepatitis, and gall bladder disorders. Further, in our previous studies, we explored the anti-cancer efficacy in common cancers, such as lung, prostatic, colon, breast, bladder, as well as, hepatocellular carcinoma. Interestingly, silibinin is still not solely limited to the treatment of these diseases. Recent research endeavors suggest that silibinin may function diversely and serve as a novel therapy for hematological disorders. AREAS COVERED: It discovered several interesting viewpoints in the widely studied mechanisms of silibinin in the hematological disorders. EXPERT COMMENTARY: In this report, we review the up-to-date findings of more potency roles of silibinin in β-thalassemia (β-TM), acute myeloid leukemia (AML), anaplastic large cell lymphoma (ALCL) and multiple myelomas (MM) therapy and attempt to clarify the mechanisms underlying its effects. There are two viewpoints: First, The functional mechanisms of silibinin in AML cells via regulating cell differentiation to exert anti-cancer effect; Second, combination treatment strategy may be a good choice. Impact Journals LLC 2017-07-11 /pmc/articles/PMC5687691/ /pubmed/29179521 http://dx.doi.org/10.18632/oncotarget.19153 Text en Copyright: © 2017 Zou et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Zou, Hai Zhu, Xing-Xing Zhang, Guo-Bing Ma, Yuan Wu, Yi Huang, Dong-Sheng Silibinin: an old drug for hematological disorders |
title | Silibinin: an old drug for hematological disorders |
title_full | Silibinin: an old drug for hematological disorders |
title_fullStr | Silibinin: an old drug for hematological disorders |
title_full_unstemmed | Silibinin: an old drug for hematological disorders |
title_short | Silibinin: an old drug for hematological disorders |
title_sort | silibinin: an old drug for hematological disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687691/ https://www.ncbi.nlm.nih.gov/pubmed/29179521 http://dx.doi.org/10.18632/oncotarget.19153 |
work_keys_str_mv | AT zouhai silibininanolddrugforhematologicaldisorders AT zhuxingxing silibininanolddrugforhematologicaldisorders AT zhangguobing silibininanolddrugforhematologicaldisorders AT mayuan silibininanolddrugforhematologicaldisorders AT wuyi silibininanolddrugforhematologicaldisorders AT huangdongsheng silibininanolddrugforhematologicaldisorders |